Clinicians often believe that cachexia is caused by cancer and anorexia as a toxicity of
chemotherapy or targeted anti-cancer agents. It is now recognized that chemotherapy and …

Opinion statement Sarcopenia is being consistently recognized as a condition not only
associated with the presence of a malignancy but also induced by the oncologic therapies …

Background/Aim: Skeletal muscle mass loss is an emerging concern in oncology. Our
systematic review and meta-analysis identified the mean difference in skeletal muscle index …

Paraneoplastic conditions such as cancer cachexia are often exacerbated by chemotherapy,
which affects the patient's quality of life as well as the response to therapy. The aim of this …

Body composition analysis, also referred to as analytic morphomics, morphomics, or
morphometry, describes the measurement of imaging biomarkers of body composition such …

In cancer patients, chemotherapeutic medication induces aberrant ROS (reactive oxygen
species) accumulation in skeletal muscles, resulting in myofiber degradation, muscle …

Background In patients with acute and chronic illness, depleted skeletal muscle (SM) mass,
also referred to as sarcopenia, is a condition associated with an underlying disease process …

Background Frailty, sarcopenia and malnutrition are powerful predictors of clinical outcomes
that are not routinely measured in patients with non-small cell lung cancer (NSCLC). The …

Background In recent years, the research on the relationship between sarcopenia before
and after the treatment of esophageal cancer, as well as its impact on prognosis of …

Background Cisplatin-based chemotherapy is the first line of treatment for bladder cancer.
However, cisplatin induces muscle wasting associated with NF-κB and cancer cachexia …